St. Teresa Medical
Developer of a soft-matter nanotechnology platform based on electrospun dextran nanofibers that deliver human clotting proteins for resorbable, non‑swelling topical hemostatic dressings. The company has performed GLP and non‑GLP preclinical studies, completed multi‑center human clinical studies for bone bleeding, holds issued and pending patents on electrospun dextran fiber devices, and is advancing pilot production toward GMP manufacturing and regulatory filings.
Industries
N/A
Nr. of Employees
small (1-50)
St. Teresa Medical
2915 Waters Road, Suite 108, Eagan, Minnesota 55121, USA
Patents
Products
Dissolvable fibrin sealant patch for cancellous bone bleeding
A resorbable topical fibrin sealing dressing fabricated from electrospun dextran nanofibers that deliver human thrombin and fibrinogen; designed to rapidly achieve local hemostasis without swelling and to resorb over time.
Dissolvable fibrin sealant patch for cancellous bone bleeding
A resorbable topical fibrin sealing dressing fabricated from electrospun dextran nanofibers that deliver human thrombin and fibrinogen; designed to rapidly achieve local hemostasis without swelling and to resorb over time.
Services
Pilot production development and preparation for GMP-compliant manufacturing to support product commercialization.
Design and execution support for human clinical studies and investigator-initiated research, including trial protocols and multi-center study coordination.
Engagement and onboarding for regional distributors to support market access and product distribution.
Pilot production development and preparation for GMP-compliant manufacturing to support product commercialization.
Design and execution support for human clinical studies and investigator-initiated research, including trial protocols and multi-center study coordination.
Engagement and onboarding for regional distributors to support market access and product distribution.
Expertise Areas
- Topical hemostatic dressing development
- Electrospun nanofiber biomaterials
- Preclinical GLP and in vivo efficacy studies
- Clinical trial management for medical devices
Key Technologies
- Electrospinning
- Dextran-based nanofiber mats
- Topical fibrin sealant delivery (thrombin + fibrinogen)
- Resorbable/non-swelling hemostatic dressings
News & Updates
Announcement of enrollment of the first patient into a human clinical trial for the dissolvable fibrin sealant patch, with MHRA approval for a 40‑patient study.
Report of a clinical trial in which 10 spinal fusion patients were treated and bleeding was controlled at all 12 treated sites with a single application within 3 minutes.
Summary and link to the peer-reviewed accepted paper evaluating safety and performance of the fibrin dressing in a multi‑center study (UK, Norway, India) reporting control of bleeding at clinical endpoints.
Report of the first commercial clinical use of the dissolvable fibrin sealant patch in elective spine surgery and clinician observations on handling and efficacy.
U.S. Patent US 9,399,082 issued covering electrospun dextran fibers and devices formed therefrom, forming a key technology base for the electrospun dextran dressing platform.
Recognition (2017) for technology transfer work with government collaborators related to the dissolvable hemostatic dressing.
Announcement of enrollment of the first patient into a human clinical trial for the dissolvable fibrin sealant patch, with MHRA approval for a 40‑patient study.
Report of a clinical trial in which 10 spinal fusion patients were treated and bleeding was controlled at all 12 treated sites with a single application within 3 minutes.
Summary and link to the peer-reviewed accepted paper evaluating safety and performance of the fibrin dressing in a multi‑center study (UK, Norway, India) reporting control of bleeding at clinical endpoints.
Report of the first commercial clinical use of the dissolvable fibrin sealant patch in elective spine surgery and clinician observations on handling and efficacy.
U.S. Patent US 9,399,082 issued covering electrospun dextran fibers and devices formed therefrom, forming a key technology base for the electrospun dextran dressing platform.
Recognition (2017) for technology transfer work with government collaborators related to the dissolvable hemostatic dressing.